CLAIMS

1. A compound of Formula I



(I)

an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug;

wherein W is (a) -O-, (b) $-S(O)_m-$, (c) $-NR^{30}-$, (d) -C(O)-, (e) -HC=CH-, (f) $-CH_2-$, (g) -CHF-, (h) $-CF_2-$ or (i) -CH(OH)-;

R^1 and R^2 are independently (a) hydrogen, (b) halogen, (c) $-(C_1-C_6)$alkyl, (d) -CN, (e) $-OR^{12}$ or (f) -trifluoromethyl;

R^3 is (a) hydrogen, (b) halogen, (c) $-(C_1-C_6)$alkyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, $-OCF_3$ and $-CF_3$, (d) -CN, (e) $-OR^{12}$, (f) -trifluoromethyl, (g) $-NO_2$, (h) $-SO_2-R^{13}$, (i) $-C(O)_2R^9$, (j) $-C(O)NR^{19}R^{20}$, (k) $-C(O)R^{16}$, (l) $-NR^{21}C(O)-NR^{21}R^{22}$, (m) $-NR^{19}-C(O)R^{20}$ or (n) $-NR^{17}R^{18}$;

R^4 is (a) $-C(R^{14})(R^{15})(R^{16})$, (b) $-(C_0-C_3)$alkyl-$NR^{17}R^{18}$, (c) $-C(O)NR^{19}R^{20}$, (d) $-NR^{19}-C(O)-R^{20}$, (e) $-(C_0-C_3)$alkyl-$NR^{21}-C(O)-NR^{21}R^{22}$, (f) $-S(O)_m-R^{22}$, (g) $-S(O)_2-NR^{21}R^{22}$, (h) $-NR^{21}-S(O)_2-R^{22}$, (i) -aryl, (j) -het, (k) $-OR^{33}$ or (l) halogen; provided that in substituents (f) and (h), R^{22} is other than $-OR^{34}$; and provided that when substituent (b) is $-(C_0)$alkyl-$NR^{17}R^{18}$, R^{18} is other than $-C(O)-R^{28}$ or $-S(O)_2-R^{29}$;

or R^3 and R^4 may be taken together to form a carbocyclic ring of Formula $-(CH_2)_b-$ or a heterocyclic ring selected from the group consisting of $-Q-(CH_2)_c-$ and $-(CH_2)_j-Q-(CH_2)_k-$ wherein Q is O, S or NR^{25}; wherein said carbocyclic ring is optionally substituted with one or more substituents independently selected from Group V; and wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from Group Z;

R^5 is $-OR^{23}$;

or R^4 and R^5 may be taken together to form a heterocyclic ring selected from the group consisting of $-CR^{31}=CR^{32}-NH-$, $-N=CR^{31}-NH-$, $-CR^{31}=CR^{32}-O-$ and $-CR^{31}=CR^{32}-S-$;

R^6 is (a) hydrogen, (b) halogen, (c) $-(C_1-C_6)$alkyl optionally substituted with one to three substituents independently selected from the group consisting of halogen, $-OCF_3$ and $-CF_3$, (d) -CN, (e) $-OR^{12}$, (f) -trifluoromethyl, (g) $-NO_2$, (h) $-SO_2-R^{13}$, (i) $-C(O)_2R^9$, (j) $-C(O)NR^{19}R^{20}$, (k) $-C(O)R^{16}$, (l) $-NR^{21}C(O)NR^{21}R^{22}$, (m) $-NR^{19}-C(O)R^{20}$ or (n) $-NR^{17}R^{18}$;

R^7 is (a) hydrogen, (b) $-(C_1-C_4)$alkyl wherein each carbon atom is optionally substituted with 1 to 3 halo atoms or (c) $-(CH_2)_nCOOR^9$;

R^8 is (a) hydrogen, (b) $-(C_1-C_6)$alkyl, (c) $-C(O)-OR^9$, (d) $-C(O)NR^{10}R^{11}$ or (e) -CN; provided that in substituent (c), R^9 is other than methyl or ethyl; and provided that in substitutent (d), R^{10} and R^{11} are not both hydrogen;

R^9 is (a) $-(C_1-C_{12})$alkyl optionally substituted with one or more substitutents independently selected from Group V, (b) $-(C_2-C_{12})$alkenyl optionally substituted with phenyl, (c) $-(C_2-C_{12})$dialkenyl, (d) $-(C_3-C_{10})$cycloalkyl, (e) -aryl or (f) -het;

R^{10} and R^{11} are independently (a) hydrogen, (b) $-(C_1-C_{12})$alkyl optionally substituted with one or more substituents independently selected from Group V, (c) $-(C_3-C_{10})$cycloalkyl optionally substituted with one or more substituents independently selected from Group V, (d) $-(C_2-C_{12})$alkenyl or (e) -het;

or R^{10} and R^{11} for any occurrence may be taken together with the nitrogen atom to which are they attached to form het;

R^{12} is (a) hydrogen or (b) $-(C_1-C_6)$alkyl wherein each carbon atom is optionally substituted with 1 to 3 fluoro atoms;

R^{13} is (a) $-(C_1-C_{12})$alkyl optionally substituted with one or more substituents independently selected from Group V, (b) $-(C_2-C_{12})$alkenyl, (c) $-(C_3-C_{10})$cycloalkyl, (d) $-NR^{17}R^{18}$, (e) -aryl or (f) -het;

R^{14} is (a) hydrogen, (b) $-(C_1-C_6)$alkyl or (c)-O-R^{34};

R^{15} is (a) hydrogen or (b) $-(C_1-C_6)$alkyl;

or R^{14} and R^{15} are taken together with the carbon atom to which they are attached to form a carbonyl group;

R^{16} is (a) hydrogen, (b) -(C_1-C_6)alkyl wherein each carbon atom is optionally substituted with 1 to 3 fluoro atoms, (c) -(C_0-C_6)alkyl-(C_3-C_{10})cycloalkyl, (d) -(C_0-C_6)alkyl-aryl or (e) -(C_0-C_6)alkyl-het;

R^{17} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -aryl, (d) -het, (e) -OR^{34} or (f) -(C_3-C_{10})cycloalkyl;

R^{18} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -aryl, (d) -het, (e) -C(O)-R^{28}, (f) -$S(O)_2$-R^{29}, (g) -OR^{34} or (h) -(C_3-C_{10})cycloalkyl;

or R^{17} and R^{18} for any occurrence are taken together with the nitrogen atom to which they are attached to form het;

R^{19} and R^{20} for each occurrence are independently (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -(C_0-C_6)alkyl-aryl, (d) -(C_0-C_6)alkyl-het, (e) -C(O)-$NR^{26}R^{27}$, (f) -C(O)-R^{28}, (g) -$S(O)_2$-R^{29}, (h) -OR^{34} or (i) -(C_3-C_{10})cycloalkyl;

or R^{19} and R^{20} for any occurrence are taken together with the nitrogen atom to which they are attached to form het;

R^{21} and R^{22} for each occurrence are independently (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one to three substituents independently selected from Group V, (c)-aryl, (d) -het, (e) -(C_3-C_{10})cycloalkyl or (f) -OR^{34};

or R^{21} and R^{22} are taken together with the nitrogen atom to which they are attached to form het;

R^{23} is (a) hydrogen, (b) -(C_1-C_4)alkyl optionally substituted with one or more substituents independently selected from Group V or (c) -C(O)-R^{24};

R^{24} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -(C_2-C_{12})alkenyl, (d) -(C_3-C_{10})cycloalkyl, (e) -aryl or (f) -het;

R^{25} for each occurrence is independently (a) hydrogen, (b) -(C_1-C_6)alkyl, (c) -COR^{29} or (d) -SO_2R^{29};

R^{26} and R^{27} for each occurrence are independently (a) hydrogen, (b) -(C_1-C_6)alkyl, (c) -(C_3-C_{10})cycloalkyl, (d) -(C_0-C_6)alkyl-aryl, or (e) -(C_0-C_6)alkyl-het,

R^{28} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -(C_2-C_{12})alkenyl, (d) -(C_3-C_{10})cycloalkyl, (e) -aryl or (f) -het;

R^{29} is (a) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (b) -(C_2-C_{12})alkenyl, (c) -(C_3-C_{10})cycloalkyl, (d) -aryl or (e) -het;

R^{30} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -(C_1-C_{12})alkenyl, (d) -(C_3-C_{10})cycloalkyl, (e) -C(O)-R^{31} or (f) -$S(O)_m$-R^{32};

R^{31} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -(C_2-C_{12})alkenyl, (d) -(C_3-C_{10})cycloalkyl, (e) –aryl, (f) –het or (g) –OR^{34};

R^{32} is (a) hydrogen, (b) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (c) -(C_2-C_{12})alkenyl, (d) -(C_3-C_{10})cycloalkyl, (e) -aryl or (f) –het;

R^{33} is (a) -(C_0-C_6)alkyl-aryl, (b) -(C_0-C_6)alkyl-het, (c) -(C_7-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (d) -(C_1-C_6)alkyl wherein at least one carbon atom is substituted with 1 to 3 fluoro atoms, (e) -(C_2-C_{12})alkenyl or (f) -(C_3-C_{10})cycloalkyl;

R^{34} is (a) -aryl, (b) -het , (c) -(C_1-C_{12})alkyl optionally substituted with one or more substituents independently selected from Group V, (d) -(C_2-C_{12})alkenyl or (e) -(C_3-C_{10})cycloalkyl;

-(C_3-C_{10})cycloalkyl for each occurrence is a fully or partially saturated mono-, bi- or tricyclic ring containing three to ten carbon atoms; wherein in the bicyclic ring, a monocyclic cycloalkyl ring is spiro fused to another cycloalkyl ring or is fused via two carbon atoms to a benzene ring or another cycloalkyl ring; and wherein in the tricyclic ring, a bicyclic ring is spiro fused to a cycloalkyl ring or is fused via two atoms to a benzene ring or another cycloalkyl ring;

said -(C_3-C_{10})cycloalkyl optionally contains one to three bridging atoms independently selected from carbon, oxygen, sulfur and nitrogen; said bridging atoms are attached to two carbon atoms in the ring; and said bridging atoms are optionally substituted with one to three groups independently selected from -(C_1-C_6)alkyl and hydroxy;

said cycloalkyl ring is optionally substituted on one ring if the moiety is monocyclic, on one or both rings if the moiety is bicyclic, or on one, two or three rings if the moiety is tricyclic, with one or more substitutents independently selected from Group V;

Group V is (a) -(C_1-C_6)alkyl optionally substituted with one or two hydroxy, (b) -(C_2-C_5)alkynyl, (c) -halogen, (d) -$NR^{35}R^{36}$, (e) -NO_2, (f) -OCF_3, (g) -OR^{37}, (h) -SR^{37}, (i) -oxo, (j) -trifluoromethyl, (k) -CN, (l) -$C(O)NR^{35}$-OH, (m) -$COOR^{35}$, (n) -O-C(O)-(C_1-C_6)alkyl, (o) -(C_3-C_{10})cycloalkyl optionally substituted with CN, (p) -(C_0-C_6)alkyl-aryl, (q) -(C_0-C_6)alkyl-het, (r) -C(O)-(C_1-C_6)alkyl or (s) -C(O)-aryl;

R^{35} and R^{36} for each occurrence are independently (a) hydrogen, (b) -(C_1-C_6)alkyl or (c) -(C_0-C_6)alkyl-aryl;

R^{37} is (a) hydrogen, (b) -(C_1-C_6)alkyl optionally substituted with one or more halo, hydroxy or methoxy, (c) -(C_0-C_6)alkyl-aryl or (d) -(C_0-C_6)alkyl-het;

aryl is (a) phenyl optionally substituted with one or more substituents independently selected from Group Z; (b) naphthyl optionally substituted with one or more substituents independently selected from Group Z or (c) biphenyl optionally substituted with one or more substituents independently selected from Group Z;

het for each occurrence is a 4-, 5-, 6-, 7- and 8-membered fully saturated, partially saturated or fully unsaturated mono-, bi- or tricyclic heterocyclic ring containing from one to four heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen; wherein in the bicyclic ring, a monocyclic heterocyclic ring is spiro fused to a -(C_3-C_8)cycloalkyl ring or to another heterocyclic ring which is fully or partially saturated; or is fused via two atoms to a benzene ring, a -(C_3-C_8)cycloalkyl ring or another heterocyclic ring; and wherein in the tricyclic ring, a bicyclic ring is spiro fused to a -(C_3-C_8)cycloalkyl ring or to another heterocyclic ring which is fully or partially saturated; or is fused via two atoms to a benzene ring, a (C_3-C_6)cycloalkyl ring, or another heterocyclic ring;

said het optionally contains one to three bridging atoms independently selected from oxygen, sulfur and nitrogen; said bridging atoms are attached to two other atoms in the ring; and said bridging atoms are optionally substituted with one to three groups independently selected from -(C_1-C_6)alkyl and hydroxy;

said het optionally has one or two oxo groups substituted on carbon or one or two oxo groups substituted on sulfur;

said het is optionally substituted on carbon or nitrogen, on one ring if the moiety is monocyclic, on one or both rings if the moiety is bicyclic, or on one, two or three rings if the moiety is tricyclic, with one or more substituents independently selected from Group Z;

Group Z for each occurrence is independently (a) hydrogen, (b) halogen, (c) trifluoromethyl, (d) hydroxy, (e) $-OCF_3$, (f) -CN, (g) $-NO_2$, (h) $-(C_1-C_6)$alkyl optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, halogen, $-OCF_3$ and $-CF_3$, (i) $-(C_2-C_6)$alkenyl optionally substituted with phenyl, (j) $-(C_2-C_5)$alkynyl, (k) $-(C_1-C_6)$alkoxy, (l) $-(C_0-C_6)$alkyl-phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, $-OCF_3$, $-CF_3$, $-(C_1-C_4)$alkyl, $-(C_1-C_4)$alkoxy and $-C(O)CH_3$, (m) $-(C_0-C_6)$alkyl-naphthyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, $-OCF_3$, $-CF_3$, $-(C_1-C_4)$alkyl, $-(C_1-C_4)$alkoxy and $-C(O)CH_3$, (n) $-C(O)_2R^{35}$, (o) $-(C_0-C_6)$alkyl-$C(O)NR^{35}R^{36}$, (p) $-(C_0-C_6)$alkyl-$C(O)R^{38}$, (q) $-NR^{35}R^{36}$, (r) $-NR^{35}-C(O)NR^{35}R^{36}$, (s) $-NR^{35}-C(O)R^{36}$, (t) $-OR^{37}$, (u) $-SR^{37}$, (v) $-(C_3-C_{10})$cycloalkyl, (w) $-(C_0-C_6)$alkyl-pyridinyl optionally substituted with one or more $-(C_1-C_6)$alkyl which is optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and halo, (x) $-(C_0-C_6)$alkyl-piperidinyl optionally substituted with one or more $-(C_1-C_6)$alkyl which is optionally substituted with one or more substituents independently selected from hydroxy and halo, (y) $-SO_2-R^{37}$, (z) $-SO_2-NR^{35}R^{36}$ or

(a1) -S-phenyl-CH_2OH;

R^{38} is (a) $-(C_1-C_6)$alkyl, (b) $-(C_0-C_6)$alkyl-phenyl, (c) $-(C_0-C_6)$alkyl-phenanthrenyl optionally substituted with one to three CF_3, (d) $-(C_0-C_6)$alkyl-pyrrolidinyl or (e) $-(C_0-C_6)$alkyl-morpholinyl;

or any two Z Groups for any occurrence in the same variable may be taken together to form (a) a carbocyclic ring of the formula $-(CH_2)_e-$ or (b) a heterocyclic ring selected from the group consisting of $-O(CH_2)_fO-$, $-(CH_2)_gNH-$ and -CH=CHNH-;

m is 0, 1 or 2;

n is 0, 1, 2 or 3;

b is 3, 4, 5, 6 or 7;

c, f, g, j and k are each independently 2, 3, 4, 5 or 6; and

e is 3, 4, 5, 6 or 7;

provided that in a compound of Formula I : 1) the substituent -$C(R^{14})(R^{15})(R^{16})$ in R^4 is other than $(C_1\text{-}C_4)$alkyl; and 2) R^4 is halo only when R^8 is -$C(O)\text{-}OR^9$ or -$C(O)NR^{10}R^{11}$.

2. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 1 wherein W is oxygen.

3. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 2 wherein R^1 is located at the 3 position, R^2 is located at the 5 position, R^3 is located at the 2' position, R^4 is located at the 3' position, R^5 is located at the 4' position and R^6 is located at the 5' position.

4. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 3 wherein R^3 is hydrogen, R^5 is hydroxy or methoxy, R^6 is hydrogen, R^7 is hydrogen and R^8 is hydrogen.

5. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 4 wherein R^1 and R^2 are each independently methyl, bromo or chloro.

6. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $S(O)_2NR^{21}R^{22}$; R^{21} is hydrogen or methyl; and R^{22} is (a) -$(C_5\text{-}C_8)$alkyl, (b) bicyclo[2.2.1]hept-2-yl, (c) 1,2,3,4-tetrahydro-naphthalen-1-yl, (d) cyclobutyl, (e) cyclopentyl, (f) cyclohexyl or (g) phenyl optionally substituted with one or more fluoro.

7. A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R^1 is methyl or chloro, R^2 is methyl or chloro, R^5 is hydroxy and R^{21} is hydrogen.

8. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $S(O)_2NR^{21}R^{22}$; R^{21} and R^{22} are taken together with the nitrogen atom to which they are attached to form het; and het is (a) piperidinyl optionally substituted with one or more substituents independently selected from the group consisting of methyl and phenyl, (b) pyrrolidinyl, (c)1,3,3-trimethyl-6-aza-bicyclo[3.2.1]octanyl, (d) indolinyl, (e) spiro[8-azabicyclo[3.2.1]octane-3,2'-(3'H)-dihydro-furan], (f) spiro[8-azabicyclo[3.2.1]octane-3,2'-[1,3]dioxolane] or (g) 8-aza-bicyclo[3.2.1]octanyl optionally substituted with one or more substituents independently selected from the group consisting of oxo and hydroxy.

9. A compound or pharmaceutically acceptable salt as defined in claim 8 wherein R^1 is methyl or chloro, R^2 is methyl or chloro, and R^5 is hydroxy.

10. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-C(O)NR^{19}R^{20}$, R^{19} is hydrogen; and R^{20} is (a) cyclopentyl optionally substituted with one or more $-CH_2OH$, (b) bicyclo[2.2.1]hept-2-yl optionally substituted with one or more substituents independently selected from the group consisting of $-CH_2OH$ and methyl, or (c) bicyclo[3.1.1]hept-3-yl optionally substituted with one or more methyl.

11. A compound or pharmaceutically acceptable salt as defined in claim 10 wherein R^1 and R^2 are each chloro or dibromo, and R^5 is hydroxy.

12. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-C(O)NR^{19}R^{20}$; R^{19} and R^{20} are taken together with N to form het; het is (a) piperidinyl optionally substituted with one or more substituents independently selected from the group consisting of methyl and phenyl, (b) pyrrolidinyl, (c) azepanyl, (d) indolinyl or (e) 3,4-dihydro-1H-isoquinolinyl.

13. A compound or pharmaceutically acceptable salt as defined in claim 12 wherein R^1 and R^2 are each chloro and R^5 is hydroxy.

14. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-CH_2-NR^{17}R^{18}$; R^{17} is hydrogen; and R^{18} is (a) phenyl optionally substituted with one or more substituents independently selected from methyl and fluoro, (b) benzo[1,3]dioxol-5-yl or (c) indanyl.

15. A compound or pharmaceutically acceptable salt as defined in claim 14 wherein R^1 and R^2 are each chloro or bromo and R^5 is hydroxy.

16. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-CH_2-NR^{17}R^{18}$; R^{17} and R^{18} are taken together with the nitrogen atom to which they are attached to form het; and het is piperidinyl optionally substituted with one or more methyl.

17. A compound or pharmaceutically acceptable salt as defined in claim 16 wherein R^1 and R^2 are each chloro and R^5 is hydroxy.

18. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-NR^{19}-C(O)-R^{20}$; R^{19} is hydrogen; and R^{20} is (a) cyclohexyl, (b) phenyl optionally substituted with one or more substituents independently selected from the group consisting of $-OCF_3$, -fluoro and $-CF_3$, (c) -isoxazolyl optionally substituted with methyl or (d) $-(C_3-C_5)$alkyl.

19. A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R^1 and R^2 are each chloro and R^5 is hydroxy.

20. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-S(O)_2R^{22}$; and R^{22} is (a) phenyl optionally substituted with one or more substituents independently selected from the group consisting of methyl and ethyl, (b) indanyl or (c) $-(CH_2)-(C_4-C_6)$ cycloalkyl.

21. A compound or pharmaceutically acceptable salt as defined in claim 20 wherein R^1 and R^2 are each chloro and R^5 is hydroxy.

22. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 3 wherein R^1 and R^2 are each independently chloro or methyl; R^3 is hydrogen; R^4 and R^5 are taken together to form 

; R^6 is hydrogen; and R^{32} is hydrogen or methyl.

23. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 3 wherein R^3 is hydrogen, R^4 is Br, R^5 is hydroxy or methoxy, R^6 is hydrogen and R^7 is hydrogen.

24. A compound or pharmaceutically acceptable salt as defined in claim 23 wherein R^1 and R^2 are each methyl.

25. A compound or pharmaceutically acceptable salt as defined in claim 24 wherein R^8 is $-C(O)NR^{10}R^{11}$; R^{10} is hydrogen; and R^{11} is (a) $-CH_2$-furanyl (b) $-CH_2$-phenyl optionally substituted with one or more CF_3, (c) $-CH_2$-cyclohexyl optionally substituted with one or more CN, (d) $-CH_2$-pyridinyl, (e) $-(CH_2)_3$-imidazolyl or (f) $-(CH_2)_2-N(CH_3)_2$.

26. A compound or pharmaceutically acceptable salt as defined in claim 24 wherein R^8 is $-C(O)NR^{10}R^{11}$; R^{10} and R^{11} are taken together with the nitrogen atom to which they are attached to form het; and het is (a) thiazolidinyl or (b) 4-oxo-piperidinyl optionally substituted with one or more carboxylic acid methyl ester.

27. A compound or pharmaceutically acceptable salt as defined in claim 24 wherein R^8 is $-C(O)OR^9$; and R^9 is $-(CH_2)_2$-piperazinyl optionally substituted with one or more 4-acetyl-phenyl.

28. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-C(R^{14})(R^{15})(R^{16})$; R^{14} is hydroxy; R^{15} is hydrogen; and R^{16} is (a) phenyl optionally substituted with one or more fluoro or (b) $-(C_1-C_5)$alkyl.

29. A compound or pharmaceutically acceptable salt as defined in claim 28 wherein R^1 is methyl, chloro or bromo; and R^2 is methyl, chloro or bromo.

30. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-C(R^{14})(R^{15})(R^{16})$; R^{14} is hydrogen or methyl; R^{15} is hydrogen; and R^{16} is (a) phenyl optionally substituted with one or more fluoro or (b) $-(C_1-C_5)$alkyl.

31. A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R^1 is methyl, chloro or bromo; R^2 is methyl, chloro or bromo; and R^5 is hydroxy.

32. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-C(R^{14})(R^{15})(R^{16})$; R^{14} and R^{15} are taken together with the carbon atom to which they are attached to form a carbonyl group; and R^{16} is (a) phenyl optionally substituted with one or more fluoro (b) or $-(C_1-C_5)$alkyl.

33. A compound or pharmaceutically acceptable salt as defined in claim 32 wherein R^1 is methyl, chloro or bromo; R^2 is methyl, chloro or bromo; and R^5 is hydroxy.

34. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $-NR^{21}-C(O)-NR^{21}R^{22}$; each R^{21} is hydrogen; and R^{22} is phenyl optionally substituted with one or more chloro.

35. A compound or pharmaceutically acceptable salt as defined in claim 34 wherein R^1 and R^2 are each methyl or chloro; and R^5 is hydroxy.

36. A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R^4 is $NR^{21}-S(O)_2-R^{22}$; R^{21} is hydrogen; and R^{22} is $-(C_0-C_2)$alkyl-phenyl optionally substituted with one or more fluoro.

37. A compound or pharmaceutically acceptable salt as defined in claim 36 wherein R^1 is chloro, methyl or bromo; R^2 is chloro, methyl or bromo; and R^5 is hydroxy.

38. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 1 wherein said compound is selected from the group consisting of:

8-[[5-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazine-2(3H)-yl)phenoxy]-2-hydroxyphenyl]sulfonyl]-spiro[8-azabicyclo[3.2.1]octane-3,2'-(3'H)-dihydro-furan];

2-{3,5-dichloro-4-[3-(3,3-dimethyl-piperidine-1-sulfonyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione;

2-{3,5-dichloro-4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidine-1-sulfonyl)-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione;

N-cyclohexyl-5-[2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-2-hydroxy-benzenesulfonamide;

N-bicyclo[2.2.1]hept-2-yl-5-[2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-2-hydroxy-benzamide;

2-{3,5-dichloro-4-[3-(3,3-dimethyl-piperidine-1-carbonyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione;

N-bicyclo[2.2.1]hept-2-yl-5-[2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-2-hydroxy-benzamide;

5-[2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-N-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl)-2-hydroxy-benzamide;

2-{3,5-dichloro-4-[3-(3,5-dimethyl-piperidine-1-carbonyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione; and

2-{3,5-dichloro-4-[4-hydroxy-3-(piperidine-1-carbonyl)-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione.

39. A compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 1 wherein said compound is selected from the group consisting of:

2-[3-Chloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3,5-Dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3,5-Dimethyl-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3-Chloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3,5-Dichloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3,5-Dimethyl-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3-Chloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-2H-[1,2,4]triazine-3,5-dione;

2-[3,5-Dichloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-2H-[1,2,4]triazine-3,5-dione; and

2-[3,5-Dimethyl-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-2H-[1,2,4]triazine-3,5-dione.

40. A method of treating a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug.

41. A method as defined in claim 40 wherein said condition is obesity.

42. A method as defined in claim 40 further comprising administering an anorectic agent.

43. A method as defined in claim 40 further comprising administering a lipase inhibitor.

44. A pharmaceutical composition comprising an amount of a compound of claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

45. A pharmaceutical composition for treating a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure in a mammal comprising an amount of a compound of claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

46. A pharmaceutical composition as defined in claim 45 wherein said condition is obesity.

47. A pharmaceutical composition as defined in claim 45 further including an anorectic agent.

48. A pharmaceutical composition as defined in claim 45 further including a lipase inhibitor.

49. A kit for the treatment of a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure which comprises:

a first compound, said first compound being a compound of claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug and a pharmaceutically acceptable carrier, vehicle or diluent, in a first unit dosage form;

a second compound, said second compound being useful for the treatment of a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure, and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

a container for containing said first and second dosage forms; wherein the amounts of said first and second compounds result in a therapeutic effect.

50. A kit as defined in claim 49 wherein the second compound is an anorectic agent.

51. A kit as defined in claim 49 wherein the second compound is a lipase inhibitor.

52. A kit as defined in claim 49 wherein said condition is obesity.

53. A method of treating a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically

acceptable salt of said compound, isomer or prodrug, in combination with at least one additional compound useful for treating a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure.

54. A pharmaceutical composition comprising an amount of a compound of claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug; at least one additional compound useful for treating a condition selected from the group consisting of obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure in a mammal; and a pharmaceutically acceptable carrier, vehicle or diluent.